// App-Quantinova.ai

: Potential Safety Concern of Daprodustat Compared with Injectable Erythropoiesis-Stimulating Agents in Patients with Anemia on Hemodialysis and Not on Dialysis: A Pooled Analysis

Researchers

Presenter

  • TakayukiHamano

Principal Investigators

  • MasaomiNangaku

  • TadaoAkizawa

  • YoshiharuTsubakihara

  • TakashiNagakubo

  • TaekoYonekawa

  • ToshifumiKimura

  • YukihiroEndo

  • AlexanderRalphCobitz

Medical Centers

  • Osaka University Graduate School of Medicine, Suita, Japan

  • The University of Tokyo Graduate School of Medicine, Tokyo, Japan

  • The Jikei University School of Medicine, Tokyo, Japan

  • Graduate School of Health Care Science, Jikei Institute, Yodogawa-ku, Osaka, Japan

  • Glaxosmithkline, Tokyo, Japan,

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Ophthalmology (OP)

  • Central Nervous System (CNS)

  • Oncology (ONC)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

Disease

  • Age-Related Macular Degeneration

  • Myocardial infarction

  • Congestive heart failure

  • Diabetic retinopathy

  • Venous thrombosis

  • Anemia

  • Solid malignancies

  • Stroke

Biomarkers

  • Epithelial Cell Adhesion Molecule

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • NA

Study Id's

  • NCT01977573

  • NCT02791763

  • NCT02969655

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved